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Border Security: The Role of RIPK3 in
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Kenta Moriwaki †, Sakthi Balaji and Francis Ka-Ming Chan*
Department of Pathology, Immunology and Microbiology Program, University of Massachusetts Medical School, Worcester,
MA, USA
Receptor interacting protein kinase 3 (RIPK3) is a crucial inducer of necroptosis. Its
activity is controlled by interaction with other signal adaptors through the “RIP homotypic
interaction motif” (RHIM). Recent studies revealed a critical function for RIPK3 in the
maintenance of epithelial tissue integrity. In mice with genetic deficiency of the apoptosis
adaptors FADD or caspase 8, RIPK3 promotes necroptotic cell death of epithelial cells,
leading to excessive and lethal inflammation. In contrast, when FADD and caspase
8 functions are intact, RIPK3 serves as a protector of intestinal epithelial integrity by
promoting injury-induced wound repair. In the latter case, RIPK3 promotes optimal
cytokine expression by cells of hematopoietic origin. Specifically, bone marrow derived
dendritic cells (BMDCs) have an obligate requirement for RIPK3 for optimal secretion
of mature IL-1β and other inflammatory cytokines in response to toll-like receptor 4
(TLR4) stimulation. RIPK3 promotes cytokine expression through two complementary
mechanisms: NF-κB dependent gene transcription and processing of pro-IL-1β. We
propose that RIPK3 functions in different cell compartments to mediate inflammation
through distinct mechanisms.
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INTRODUCTION
Epithelial tissues are the first lines of defense against pathogens and environmental insults. Genetic
experiments in mice show that many adaptors of the TNF receptor pathway have critical functions
in maintenance of epithelial integrity in the skin and intestine. The receptor interacting protein
kinases (RIPKs) are critical regulators of cell death and inflammatory signaling by TNF-like death
receptors, toll-like receptor 3 (TLR3) and TLR4 (Chan et al., 2015; Pasparakis and Vandenabeele,
2015). RIPK1 and RIPK3, the two key kinases that regulate cell death by these receptors, have
important functions in regulating inflammation at epithelial surfaces. Despite their well-known
roles in cell death, emerging evidence indicates that RIPK1 and RIPK3 are key protectors of
epithelial integrity. Another surprising realization is that rather than acting in synergy, these two
kinases can sometimes exert opposing effects in epithelial tissues. Here, we will discuss recent
studies that led to these emerging themes. We will also provide some experimental data from an
intestinal injury model to illustrate the influence of commensal microbiota on RIPK3-mediated
tissue protection and the long-term consequence of RIPK3 deficiency on chronic injury-induced
inflammation.
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RIPK1 AND RIPK3 MEDIATE
TNF-INDUCED CELL DEATH SIGNALS
TNF is a pleiotropic cytokine that exerts its biological effects
through binding to two distinct cell surface receptors, TNFR1
(p55/p60) and TNFR2 (p75/p80). TNFR1 is constitutively
expressed in most cells, while TNFR2 expression is inducible
in response to activation signals (Kim and Teh, 2004). While
most of the biological effects of TNF can be attributed to the
action of TNFR1, genetic evidence suggests that TNFR2 can
sometimes function independently of TNFR1 (Kim and Teh,
2001, 2004; Dayer Schneider et al., 2009; Kim et al., 2009). Despite
the name tumor necrosis factor, TNF predominantly stimulates
gene transcription through theMAP kinase andNF-κB pathways.
The NF-κB pathway downstream of TNFR1 has been extensively
studied and has a pivotal role in expression of pro-survival factors
such as the cellular FLICE (aka caspase 8)-like inhibitor protein
(cFLIP) and the cellular inhibitor of apoptosis protein 1 (cIAP1)
and cIAP2. Since TNFR2 stimulates proteasomal degradation of
the E3 ligases cIAP1 and cIAP2 and the adaptor protein TRAF2
[(Csomos et al., 2009) and unpublished results], cells that express
TNFR1 and TNFR2 are much more sensitive to TNF-induced
apoptosis than cells expressing only TNFR1 (Chan and Lenardo,
2000). Apoptosis induced in the absence of the cIAPs requires
RIPK1 kinase activity (Wang et al., 2008).When caspase 8 activity
is inhibited, TNF stimulates “necroptosis,” a form of regulated
necrosis marked by rapid loss of plasma membrane integrity.
TNF-induced necroptosis requires activation of the RIPK1-
RIPK3-mixed lineage kinase domain-like (MLKL) axis (Chan
et al., 2015). Because of the leakage of cellular damage-associated
molecular patterns (DAMPs) from necroptotic cells, necroptosis
is a more inflammatory form of cell death than apoptosis
(Aaes et al., 2016). Thus, TNF can stimulate inflammation
through at least two distinct mechanisms, NF-κB-dependent
gene expression and necroptosis (Figure 1A).
GENETIC ABLATION OF FADD OR
CASPASE 8 PRIMES EPITHELIAL CELLS
TO NECROPTOSIS
Both RIPK1 and RIPK3 are cleavage substrates of caspase 8
(Lin et al., 1999; Feng et al., 2007). Cleavage of RIPK1 and
RIPK3 inactivates their pro-necrotic activity (Cho et al., 2009;
He et al., 2009). Hence, necroptosis is optimally induced when
caspase 8 or its adaptor FADD is inhibited (Figure 1A). This
yin-yang relationship between caspase-dependent apoptosis and
RIPK-mediated necroptosis is highlighted during embryonic
development in which genetic deletion of FADD or caspase 8 led
to embryonic lethality on E10.5 (Yeh et al., 1998; Zhang et al.,
1998). This developmental defect is corrected by crossing the
mice to Ripk1−/− or Ripk3−/− mice (Kaiser et al., 2011; Oberst
et al., 2011; Zhang et al., 2011), although Fadd−/−Ripk1−/−
mice still suffered from postnatal lethality due to other RIPK1-
associated survival functions (Zhang et al., 2011; Dillon et al.,
2014; Kaiser et al., 2014; Rickard et al., 2014). Tissue specific
deletion of FADD or caspase 8 also led to spontaneous and fatal
inflammation in the respective tissues (Kovalenko et al., 2009;
Bonnet et al., 2011; Gunther et al., 2011; Welz et al., 2011).
The inflammation was marked by necrotic cell death and an
increase in inflammatory cytokine expression. Again, the disease
was reversed by deletion of Ripk3. These results led to the
popular view that RIPK3-mediated necroptosis is a key driver of
inflammation in epithelial tissues.
RIPK3 FACILITATES WOUND REPAIR IN
EPITHELIAL TISSUES
Because loss of FADD or caspase 8 compromises organismal
survival, it is unlikely to be a natural occurrence. We therefore,
questioned whether RIPK3 has similar pro-inflammatory
function in epithelial homeostasis when FADD and caspase 8
functions are intact. We tested this notion using dextran sodium
sulfate (DSS) to induce intestinal injury in Ripk3−/− mice.
DSS causes intestinal injury through unknown mechanisms,
leading to inflammation that bears some resemblance to human
colitis (Wirtz et al., 2007). The inflammatory response is
essential to initiate repair of the damaged intestinal epithelium.
Surprisingly, we found that Ripk3−/− mice were more sensitive
to DSS compared with their littermates (Moriwaki et al., 2014).
The hypersensitivity of Ripk3−/− mice was dose-dependent,
since it was observed with 3% DSS, but not at lower doses
of DSS (Figure 1B and see below). Moreover, the duration of
DSS treatment and potency of different batches of DSS can
influence the severity of disease (unpublished observation). In
addition, DSS-induced colitis is highly dependent on commensal
microbiota. For example, antibiotics treatment can exacerbate
DSS-induced colitis by expansion of certain resistant E. coli
pathobiont that stimulates the Naip5-Nlrc4 inflammasome
(Ayres et al., 2012). Consistent with these observations,
antibiotics treatment led to equally severe DSS-induced colitis in
Ripk3−/− and wild type littermates (Figure 1C). Because of the
severe diarrhea and body weight loss in the antibiotics-treated
mice, all the animals had to be euthanized on day 9. These results
suggest that RIPK3 may facilitate sensing of specific bacterial
pathogen-associated molecular patterns (PAMPs). These factors
can all affect the outcome of DSS-induced colitis and explain why
a recent study did not find Ripk3−/− mice to be more sensitive
to DSS (Newton et al., 2016).
We previously reported that epithelial cell injury was similar
in wild type and Ripk3−/− mice 4 days after DSS treatment
(Moriwaki et al., 2014). However, intestinal epithelial cell (IEC)
proliferation was severely impaired in Ripk3−/− mice (Moriwaki
et al., 2014), indicating that RIPK3 protects against DSS-induced
injury through promoting IEC regeneration and tissue repair. To
determine the long-term impact of impaired IEC regeneration,
we tracked tissue injury through day 15 post-DSS treatment.
To allow evaluation of tissue repair, the mice were returned
to normal drinking water on day 8. Under these conditions,
IEC injury continued to rise between day 7 and 10, but
was reduced by day 15 in wild type littermates (Figure 2A).
By contrast, IEC injury was sustained at elevated level in
Ripk3−/− mice on day 15 (Figure 2A). These results indicate that
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FIGURE 1 | (A) Signaling by TNFR1, TNFR2, and the availability of FADD, Caspase 8 and cellular IAPs determine the signaling outcome of TNF. (B–C) RIPK3 controls
DSS-induced colitis is dose- and commensal microbiota-dependent. (B) Change in body weight of mice treated with (A) 3% DSS-containing drinking water. (C) Mice
were treated with antibiotics cocktail (Ab) for 4 weeks prior to treatment with 3% DSS. Body weight loss was normalized to that on day 1. *p < 0.001.
impaired wound repair led to sustained tissue injury in Ripk3−/−
mice.
Sustained injury could lead to chronic elevated cytokine
expression. We therefore, examined the long-term impact of
failed wound repair on cytokine expression. Consistent with our
previous report (Moriwaki et al., 2014), expression of the repair-
associated cytokines IL-1β, IL-23, and IL-22 was reduced in
Ripk3−/− mice on day 7 (Figures 2B–D). By contrast, expression
of these cytokines was elevated in Ripk3−/− mice on day 15
(Figures 2B–D). Although we cannot rule out contribution
from other inflammatory mediators, these results are consistent
with the notion that chronic injury caused by RIPK3 deficiency
eventually led to sustained production of inflammatory
cytokines in Ripk3−/− mice. In this regard, it is interesting
to note that elevated RIPK3 expression was detected in
human patients of inflammatory bowel diseases (Pierdomenico
et al., 2014). This suggests that RIPK3 may similarly drive
inflammatory cytokine expression in human inflammatory bowel
diseases.
Chronic inflammation can promote tumorigenesis. We
therefore, asked if DSS-treated Ripk3−/− mice are more
susceptible to developing colon carcinoma. To this end, we
treated mice with a single dose of the carcinogen azoxymethane
(AOM), followed by three cycles of 2.5% DSS treatment
(Figure 2E). With the lower dose of DSS, the body weight
change was much more comparable between Ripk3−/− mice and
their wild type littermates (Figure 2E), indicating that RIPK3-
mediated tissue repair response is dose-dependent. We found
that the number of colon tumors was significantly increased in
Ripk3−/− mice (Figure 2F). These results therefore indicate that
the loss of RIPK3 promotes inflammation-induced tumorigenesis
in the colon. In contrast, a recent report shows that the RIPK1-
RIPK3 necrosome promotes pancreatic oncogenesis through
upregulation of the chemokine CXCL1 (Seifert et al., 2016).
It is noteworthy that many breast and colon tumors do not
express RIPK3 (He et al., 2009; Moriwaki et al., 2015b), while
pancreatic cancers often exhibit increased RIPK1 and RIPK3
expression (Seifert et al., 2016). These results therefore highlight
the tissue-specific effects of RIPK3 in controlling inflammation
and tumorigenesis.
The role of RIPK3 in wound repair is not restricted
to intestinal tissues. RIPK3 expression was induced during
cutaneous wound healing (Adams et al., 2007), and Ripk3−/−
mice exhibited delayed healing of dorsal cutaneous wound
(Godwin et al., 2015). In this model, Ripk3−/− mice first
exhibited reduced cytokine expression, followed by elevated
cytokine expression later in the reaction. Hence, a similar
biphasic cytokine expression pattern was observed in Ripk3−/−
mice in response to intestinal and cutaneous injury. Consistent
with a role for RIPK3 in wound repair, caspase 8, the natural
regulator of RIPK3 activity, has also been implicated in cutaneous
wound healing (Lee et al., 2009; Li et al., 2010). Based on these
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FIGURE 2 | Sustained injury in Ripk3−/− mice led to chronic elevated cytokine expression. (A) Cell injury in the intestine of DSS-treated mice was quantified
by blind histology scoring. n = 7–12. (B–D) Expression of (B) Il1b, (C) Il23p19, (D) Il22 in DSS-treated Ripk3−/− colon exhibit biphasic pattern of expression. n =
4–11. *p ≤ 0.05, **p < 0.01. (E–F) Ripk3−/− mice are more susceptible to inflammation-induced colorectal cancer. (E) Ripk3+/+ and Ripk3−/− mice were treated
with AOM and three cycles of DSS as indicated. Change in body weight of the mice is shown. Body weight loss was normalized to that on day 1. (F) The number of
tumors in the whole colon was counted on day 54. *p < 0.0001.
results, RIPK3 is likely to have a broader role in maintenance of
epithelial integrity.
RIPK3 PROMOTES INTESTINAL BARRIER
REPAIR THOUGH
NECROPTOSIS-INDEPENDENT
MECHANISMS
Recent evidence indicates that RIPK3 also has important
functions in NF-κB and NLRP3 inflammasome activation.
Indeed, these non-necroptotic activities are crucial for RIPK3-
mediated tissue repair in the damaged intestine. In bone
marrow derived dendritic cells (BMDCs), RIPK3 promotes
nuclear translocation of the atypical NF-κB dimer RelB-p50
upon stimulation of the LPS receptor TLR4 (Moriwaki et al.,
2014). This activity is distinct from that of necroptosis, since
RIPK3 kinase inhibitors had no effects on LPS-induced RelB-
p50 nuclear translocation (Moriwaki et al., 2014). As such,
Ripk3−/− BMDCs were highly defective in expression of many
inflammatory cytokines including IL-1β and IL-23 (Moriwaki
et al., 2014, 2015a), the two key repair-associated cytokines in
the DSS-induced colitis model. Importantly, RIPK3-dependent
cytokine expression was only observed with GM-CSF and IL-4
differentiated BMDCs, but not with BMDCs differentiated with
GM-CSF alone, bone marrow derived macrophages (BMDMs)
or splenic CD11c+ DCs [(Moriwaki and Chan, 2014) and data
not shown]. These results highlight the important concept that
the outcome of RIPK3 signaling is highly context- and cell
type-dependent. Identifying the relevant immune cell type in
the lamina propria that mediates these protective signals during
tissue injury will be of prime importance.
Besides NF-κB dependent cytokine gene expression, RIPK3
is also an important factor for pro-IL-1β processing, a function
that is critical for optimal IL-1β expression in response
to DSS-induced intestinal injury. The mechanism by which
RIPK3 stimulates pro-IL-1β processing differs depending on
the activity of caspase 8 and the IAPs. In BMDCs with
intact caspase 8 activity, RIPK3 forms an atypical caspase
8 activating complex that also contains FADD and RIPK1
(Moriwaki et al., 2015a). This complex can directly cleave
pro-IL-1β, or indirectly through activation of the NLRP3
inflammasome (Lawlor et al., 2015). Importantly, RIPK3 kinase
activity is dispensable for activity of this complex (Moriwaki
et al., 2015a). When caspase 8 and IAP activities are both
inhibited, RIPK3 directly engages MLKL to stimulate NLRP3
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inflammasome activation independent of RIPK1 (Kang et al.,
2015; Lawlor et al., 2015). Understanding the precise mechanism
by which RIPK3 activates the NLRP3 inflammasome is clearly
going to be a topic of intense investigation in the near
future.
RIPK1 AND RIPK3 DO NOT FUNCTION IN
SYNERGY IN EPITHELIAL TISSUES
As we have discussed already, Ripk1 or Ripk3 deficiency could
both rescue the embryonic lethality of Fadd−/− or Casp8−/−
mice. Although these genetic experiments indicate that RIPK1
and RIPK3 act in synergy to promote necroptosis, this is not
the case in epithelial tissues. In fact, RIPK1 antagonizes RIPK3
in epithelial tissues to preserve barrier integrity. For example,
skin epithelium-specific deletion of Ripk1 led to spontaneous and
lethal inflammation that was fully corrected by co-deletion of
Ripk3 (Dannappel et al., 2014). Similar spontaneous and lethal
inflammation was observed in mice with intestinal epithelium-
specific deletion of Ripk1. However, in contrast to the skin,
Ripk3 deletion alone was not sufficient to rescue the disease.
Instead, compound deficiency of Fadd and Ripk3 was required
to fully inhibit the inflammatory disease (Dannappel et al., 2014;
Takahashi et al., 2014). Interestingly, mice expressing a kinase
inactive version of RIPK1 do not develop spontaneous colitis or
skin inflammation (Berger et al., 2014; Dannappel et al., 2014;
Newton et al., 2014; Takahashi et al., 2014). Since RIPK1 kinase
activity is essential for its apoptotic and necroptotic effects, these
results indicate that the death-inducing function of RIPK1 is
not responsible for survival of epithelial tissues. Rather, RIPK1
provides a “survival scaffold” that counteracts the deleterious
effects of RIPK3 through other yet-to-be defined mechanisms.
CONCLUSION
RIPK3 is widely considered to be an inducer of inflammation
because of its role in necroptosis. With the recent discoveries that
RIPK3 can also promote NF-κB and inflammasome activation,
a more balanced view of RIPK3 biology will require integration
of these non-necroptotic signaling functions. Because non-
necroptotic signaling by RIPK3 is cell type- and context-specific,
novel mouse models such as those that will allow tissue-specific
inactivation of Ripk3 will be useful in deciphering the roles
and mechanisms of RIPK3 in epithelial inflammatory diseases.
Moreover, the studies in epithelial tissues implicate that a RIPK1
and RIPK3 “interactome” that is distinct from that of classical
necroptosis is likely involved in the maintenance of barrier
integrity. Unraveling the distinct signaling pathways in different
cell compartments that mediate these effects will therefore be a
critical endeavor in future investigations.
MATERIALS AND METHODS
Mice
Nine to 11 week old female Ripk3−/− mice and their wild type
littermates on C57BL/6J background were treated with 3% DSS
(MP Biomedicals, molecular mass 36,000–50,000 Da) for 7 days,
followed by 8 days of regular water unless otherwise stated.
For antibiotics treatment, mice were fed with drinking water
containing 1 g/L neomycin, 1 g/L ampicillin, 1 g/Lmetronidazole,
0.5 g/L vancomycin and 5 g/L sucrose for 4 weeks prior to
DSS treatment. For tumor induction, female mice (9–11 weeks)
were injected intraperitoneally with AOM (Sigma) at a dose of
10 mg/kg body weight. After 5 days, mice were administered
2.5% DSS in the drinking water for 5 days followed by 16
days of regular water. This cycle was repeated twice. In the
third cycle, mice were administered 2% DSS for 4 days followed
by 8 days of regular water. Mice were sacrificed on day 54
and tumor number was macroscopically counted. All animal
experiments were approved by the institutional animal care and
use committee.
Real-Time PCR
Total RNA was extracted from colon tissues using RNeasy
kit (Qiagen). cDNA was synthesized using Superscript
III (Invitrogen). Real-time PCR analysis using iQ SYBR
Green supermix (Bio-Rad laboratories) was performed on
C1000 thermal cycler and CFX96 real-time system (Bio-Rad
laboratories). Expression of cytokines was normalized to that of
TATA box binding protein (TBP). Primers used: Il1b: 5′- CCC
AACTGGTACATCAGCAC-3′, 5′-TCTGCTCATTCACGAAAA
GG-3′; Il22: 5′-TTGAGGTGTCCAACTTCCAGCA-3′, 5′-AGC
CGGACATCTGTGTTGTTA-3′; Il23p19: 5′- CCAGCGGGA
CATATGAATCT-3′, 5′- AGGCTCCCCTTTGAAGATGT-3′;
Tbp: 5′- CAAACCCAGAATTGTTCTCCTT-3′, 5′- ATGTGG
TCTTCCTGAATCCCT-3′.
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